scholarly journals The Indolent Nature of Primary Mucinous Carcinoma of the Ovary

2016 ◽  
Vol 1 (3) ◽  
2010 ◽  
Vol 116 (2, Part 1) ◽  
pp. 269-273 ◽  
Author(s):  
Kathleen M. Schmeler ◽  
Xia Tao ◽  
Michael Frumovitz ◽  
Michael T. Deavers ◽  
Charlotte C. Sun ◽  
...  

1991 ◽  
Vol 248 (3) ◽  
pp. 139-143 ◽  
Author(s):  
R. J. Collins ◽  
A. Cheung ◽  
H. Y. S. Ngan ◽  
L. C. Wong ◽  
S. Y. W. Chan ◽  
...  

2017 ◽  
pp. 557-563
Author(s):  
Caroline C. Billingsley ◽  
David M. Gershenson

2011 ◽  
Vol 205 (5) ◽  
pp. 480.e1-480.e8 ◽  
Author(s):  
Maria B. Schiavone ◽  
Thomas J. Herzog ◽  
Sharyn N. Lewin ◽  
Israel Deutsch ◽  
Xuming Sun ◽  
...  

1989 ◽  
Vol 33 (2) ◽  
pp. 222-224
Author(s):  
R. Soeters ◽  
W. Levin ◽  
A. Tiltman ◽  
B. Block ◽  
C.M.C. Dehaeck

2016 ◽  
pp. 221-232
Author(s):  
Jubilee Brown ◽  
Michael Frumovitz

2014 ◽  
Vol 24 (Supp 3) ◽  
pp. S14-S19 ◽  
Author(s):  
Jonathan A. Ledermann ◽  
Daniela Luvero ◽  
Aaron Shafer ◽  
Dennis O’Connor ◽  
Giorgia Mangili ◽  
...  

AbstractMucinous carcinomas of the ovary can be primary or metastatic in origin. Improvements in the pathological diagnosis have increased the ability to distinguish between primary and metastatic ovarian cancers and shown that primary mucinous carcinomas are a rare subtype of ovarian cancer. Most tumors are diagnosed at an early stage, and the prognosis after surgery is good. Advanced or recurrent mucinous carcinoma of the ovary responds poorly to current cytotoxic treatments, and the prognosis is poor. Here, we review the guidelines for surgery and the results of treatment of advanced and recurrent disease. Chemotherapy with platinum and paclitaxel is currently used to treat advanced disease, but the effect of these drugs is modest, and new treatments are needed.


Sign in / Sign up

Export Citation Format

Share Document